Refine by
Tumor Specificity Articles & Analysis: Older
77 news found
Research on molecular targeted therapy for tumors is increasing, and new targeted therapeutic agents are emerging. ...
The HZ-PEG-HZ (1K) product is critical for applications including: l Controlled Drug Delivery Systems: Leveraging its pH-sensitive hydrazone bonds for targeted and controlled release of active pharmaceutical ingredients in specific physiological environments (e.g., tumor microenvironments, endosomes, lysosomes). l Bioconjugation and Crosslinking: Facilitating the ...
Ilkka Haapala’s PhD dissertation explored the possibility of differentiating tumour types and specific mutations based on DMS. We want to congratulate Ilkka on his successful defense of the dissertation at Tampere University on 11.10.2024! IonVision was used as the DMS in several of the studies. The dissertation found that DMS can be used to identify the most common brain tumour ...
Obesity is linked with poorer PC prognosis. For those with tumors harboring a specific gene fusion, there is a greater risk of recurrence and higher all-cause and prostate cancer-specific mortality. ...
(NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, and the Translational Genomics Research Institute (TGen), part of City of Hope, today announced a partnership to explore the utility of the Nautilus platform by studying specific protein targets in diffuse intrinsic pontine glioma (DIPG), a rare and often fatal childhood ...
Its platform is commercially available worldwide now to identify tumor-specific phenotypic and genotypic fingerprints that can inform treatment selection as well as stratify patients for novel targeted therapies without the need for a training dataset or human intervention. ...
4D Path applies universal physics, biology and mathematical principles to identify tumor-specific phenotypic and genotypic fingerprints. Its system runs on modern cloud components that enable dynamic scaling and batch processing, allowing 4D to optimize run times and deliver rapid results. ...
NextPoint’s approach re-activates immune cells in tumors that are suppressed by HHLA2-driven immune evasion. NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. ...
ByBayer AG
Title: Dual targeting of innate and adaptive immune checkpoints with a PD-L1/SIRPα bispecific macrophage engager to promote anti-tumor activity Abstract No.: 1211 The anti-PDL1/SIRPα bispecific antibody ES019, designed for tumor cell and immune cell dual targeting, is capable of reactivating macrophages and T cells to kill cancer cells with the ...
About CTH-001 CTH-001 is a Cartherics’ proprietary product candidate based on autologous (i.e., patient-derived) chimeric antigen receptor (CAR)-T cells targeting tumor associated glycoprotein 72 (TAG-72). Cartherics’ researchers identified that TAG-72 is present on the aberrant T cells associated with CTCL but is essentially absent from normal T cells. ...
Cancer Vaccine Development Based on pMHC Cancer vaccines to enhance the immune response, target tumor-specific mutations not present in normal tissues, and eradicate tumors. Vaccine Development Based on VLPs with MHC Complex To demonstrate and deliver specific tumor-associated MHC complex antigens and create ...
A biomarker strategy will include evaluation of a specific, sensitive and proprietary LILRB2 antibody for immunohistochemistry to enable tumor selection with an increased probability of success. ...
Subsequent therapeutic options have relatively limited efficacy and these tumors have consistently shown poor response to current immunotherapies2. ...
For many years, he has been working on the characterization of T lymphocytes, which specifically recognize viral and tumor antigens. His research has significantly influenced the development of technology for adoptive cell transfer and vaccines. ...
ByArdigen
Partnering with SEngine ensures each patient receives the best treatment for their specific tumor,” said Dr. Pablo Prichard of Vincere. “It’s next level care; the distance we are willing to go for our patients and highest level of sophistication. ...
Oncologists can also choose from SEngine’s library of more than 240 small molecule drugs any specific options they want to test on a patient’s tumor. This round of funding will be used to accommodate the exponential growth SEngine has experienced in the past two years. ...
OnLume is developing further applications of its imaging platform, including FGS for cancer surgery, in which tumor-specific drugs could deliver fluorescent dye to cancer cells to help surgeons identify residual cancer tissue that is otherwise ...
The majority of PROTACs were created with ligands that recruit E3 ligases, which are widely expressed in tumors and normal tissues, and these PROTACs can cause off-target toxicity if the target protein is not tumor-specific. The development of tumor-specific/selective PROTACs will benefit from identifying those ...
“We are humbled by the work in front of us in partnership with Roche as we explore the anti-tumor activity of our immunotherapy candidate in combination with atezolizumab to see if our exciting results in 1st line maintenance therapy can be extended to advanced stage disease by the use of this combination of ...
AFM28 induced potent, effective, and specific anti-tumor activity against CD123-positive cells irrespective of mutational status Study demonstrated specific anti-tumor response even at low levels of CD123 expression with no evidence for off-target cytotoxic activity towards CD123-negative healthy bone marrow progenitors In ...